Cargando…
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
BACKGROUND: Despite the availability of effective antiemetics and evidence-based guidelines, up to 40% of cancer patients receiving chemotherapy fail to achieve complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced na...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452068/ https://www.ncbi.nlm.nih.gov/pubmed/28398530 http://dx.doi.org/10.1093/annonc/mdx100 |
_version_ | 1783240311088087040 |
---|---|
author | Dranitsaris, G. Molassiotis, A. Clemons, M. Roeland, E. Schwartzberg, L. Dielenseger, P. Jordan, K. Young, A. Aapro, M. |
author_facet | Dranitsaris, G. Molassiotis, A. Clemons, M. Roeland, E. Schwartzberg, L. Dielenseger, P. Jordan, K. Young, A. Aapro, M. |
author_sort | Dranitsaris, G. |
collection | PubMed |
description | BACKGROUND: Despite the availability of effective antiemetics and evidence-based guidelines, up to 40% of cancer patients receiving chemotherapy fail to achieve complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified. To incorporate these factors into the optimal selection of prophylactic antiemetics, a repeated measures cycle-based model to predict the risk of ≥ grade 2 CINV (≥2 vomiting episodes or a decrease in oral intake due to nausea) from days 0 to 5 post-chemotherapy was developed. PATIENTS AND METHODS: Data from 1198 patients enrolled in one of the five non-interventional CINV prospective studies were pooled. Generalized estimating equations were used in a backwards elimination process with the P-value set at <0.05 to identify the relevant predictive factors. A risk scoring algorithm (range 0–32) was then derived from the final model coefficients. Finally, a receiver-operating characteristic curve (ROCC) analysis was done to measure the predictive accuracy of the scoring algorithm. RESULTS: Over 4197 chemotherapy cycles, 42.2% of patients experienced ≥grade 2 CINV. Eight risk factors were identified: patient age <60 years, the first two cycles of chemotherapy, anticipatory nausea and vomiting, history of morning sickness, hours of sleep the night before chemotherapy, CINV in the prior cycle, patient self-medication with non-prescribed treatments, and the use of platinum or anthracycline-based regimens. The ROC analysis indicated good predictive accuracy with an area-under-the-curve of 0.69 (95% CI: 0.67–0.70). Before to each cycle of therapy, patients with risk scores ≥16 units would be considered at high risk for developing ≥grade 2 CINV. CONCLUSIONS: The clinical application of this prediction tool will be an important source of individual patient risk information for the oncology clinician and may enhance patient care by optimizing the use of the antiemetics in a proactive manner. |
format | Online Article Text |
id | pubmed-5452068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54520682018-03-12 The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting Dranitsaris, G. Molassiotis, A. Clemons, M. Roeland, E. Schwartzberg, L. Dielenseger, P. Jordan, K. Young, A. Aapro, M. Ann Oncol Original Articles BACKGROUND: Despite the availability of effective antiemetics and evidence-based guidelines, up to 40% of cancer patients receiving chemotherapy fail to achieve complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced nausea and vomiting (CINV) have been identified. To incorporate these factors into the optimal selection of prophylactic antiemetics, a repeated measures cycle-based model to predict the risk of ≥ grade 2 CINV (≥2 vomiting episodes or a decrease in oral intake due to nausea) from days 0 to 5 post-chemotherapy was developed. PATIENTS AND METHODS: Data from 1198 patients enrolled in one of the five non-interventional CINV prospective studies were pooled. Generalized estimating equations were used in a backwards elimination process with the P-value set at <0.05 to identify the relevant predictive factors. A risk scoring algorithm (range 0–32) was then derived from the final model coefficients. Finally, a receiver-operating characteristic curve (ROCC) analysis was done to measure the predictive accuracy of the scoring algorithm. RESULTS: Over 4197 chemotherapy cycles, 42.2% of patients experienced ≥grade 2 CINV. Eight risk factors were identified: patient age <60 years, the first two cycles of chemotherapy, anticipatory nausea and vomiting, history of morning sickness, hours of sleep the night before chemotherapy, CINV in the prior cycle, patient self-medication with non-prescribed treatments, and the use of platinum or anthracycline-based regimens. The ROC analysis indicated good predictive accuracy with an area-under-the-curve of 0.69 (95% CI: 0.67–0.70). Before to each cycle of therapy, patients with risk scores ≥16 units would be considered at high risk for developing ≥grade 2 CINV. CONCLUSIONS: The clinical application of this prediction tool will be an important source of individual patient risk information for the oncology clinician and may enhance patient care by optimizing the use of the antiemetics in a proactive manner. Oxford University Press 2017-06 2017-04-07 /pmc/articles/PMC5452068/ /pubmed/28398530 http://dx.doi.org/10.1093/annonc/mdx100 Text en © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Dranitsaris, G. Molassiotis, A. Clemons, M. Roeland, E. Schwartzberg, L. Dielenseger, P. Jordan, K. Young, A. Aapro, M. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting |
title | The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting |
title_full | The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting |
title_fullStr | The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting |
title_full_unstemmed | The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting |
title_short | The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting |
title_sort | development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452068/ https://www.ncbi.nlm.nih.gov/pubmed/28398530 http://dx.doi.org/10.1093/annonc/mdx100 |
work_keys_str_mv | AT dranitsarisg thedevelopmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT molassiotisa thedevelopmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT clemonsm thedevelopmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT roelande thedevelopmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT schwartzbergl thedevelopmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT dielensegerp thedevelopmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT jordank thedevelopmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT younga thedevelopmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT aaprom thedevelopmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT dranitsarisg developmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT molassiotisa developmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT clemonsm developmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT roelande developmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT schwartzbergl developmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT dielensegerp developmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT jordank developmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT younga developmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting AT aaprom developmentofapredictiontooltoidentifycancerpatientsathighriskforchemotherapyinducednauseaandvomiting |